More from the blog
- About us
- Dementia info
- Living with dementia
- Our scientists
- Our supporters
We were proud to partner with actress and broadcaster Shobna Gulati as she released her memoir Remember Me? just ahead of World Alzheimer’s Day in September. Shobna invited us to include an afterword to her book, which she has kindly allowed us to reproduce in full here.
I’m a consultant at Mattioli Woods, a corporate partner of Alzheimer’s Research UK, and this October, I’ll be running the London Marathon to raise funds for groundbreaking research. Well, virtually anyway!
This October, Alzheimer’s Research UK is teaming up with My Favourite Voucher Codes in their charity poll, and we would love for you to support us.
We were delighted to welcome actress and broadcaster Shobna Gulati to a special event on 16 September to mark the launch of her memoir Remember me?.
Nine months after the devastating loss of his mum to Alzheimer’s, Paul wants to do everything he can to ensure dementia research continues to make progress.
Dementia research is more critical now than ever before. That’s why we’re calling on government to deliver on its promise to double research funding for the condition, as part of a ‘Dementia Moonshot’.
Dr Susan Kohlhaas has joined Alzheimer’s Research UK as our new Director of Research.
We caught up with Dr Meghan Larin, a postdoctoral researcher, and Emma Randall, a research assistant, in Prof Vincent Dion’s lab at the UK DRI at Cardiff University.
This year, the world’s largest dementia research conference – the Alzheimer’s Association International Conference (AAIC) – went virtual. Here are our top seven highlights from the week!
We know that if we can understand what increases the risk of developing dementia, governments and individuals can be better informed about how to reduce that risk.
Times are challenging for everyone at the moment and our dementia researchers are no exception, so now more than ever it’s important to celebrate our scientists’ successes.
Now, as governments across the UK begin to ease restrictions, labs are starting to re-open and research that your support helps to fund is restarting. However, this process is complex and looks different for every lab and region.
There have been many stories in the media over the past few months about COVID-19 and dementia.
This Father’s Day I’ll be lacing up my trainers for Dad and dementia research, and here’s why.
Dementia is thought to affect around 850,000 people in the UK. Most people associate the condition with Alzheimer’s disease, the most common cause of dementia. But there are other diseases that can cause the symptoms of dementia – including frontotemporal dementia (FTD).
Have you heard the news about the partnership between Alzheimer’s Research UK and Tikiboo?
With social fundraising no longer an option, my new working from home environment meant that I had to find a different way to help, and that was to learn more about dementia.
Microscopic images reveal the hidden beauty around and within us. Dementia researchers get a unique view of the intricate but stunning workings of the brain. To showcase the fascinating insights being gained in dementia research, we ran our Science Image Competition again this year.
The COVID-19 Symptom Tracker app, developed by King’s College London, is joining forces with the UK’s largest health-based charities. The aim is to reach people most at risk of COVID-19, including those with pre-existing health conditions such as dementia, diabetes, heart disease and those over the age of 70.
You may take comfort in knowing that previous generations have found innovative ways to raise money for charity in the face of international crisis.
It’s been great to hear supporters viewing the postponement of their event as an opportunity to use the time to raise even more money for dementia research and smash their fundraising targets. It’s brilliant to know our supporters are finding a way to continue to support our work in these extraordinary times.
This latest data offers a glimmer of hope for gantenerumab. The decrease in protein levels has led the researchers and the pharmaceutical company Roche to now invite the participants to take part in an open-label extension.